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Height and timing of growth spurt during puberty in
young people living with vertically acquired HIV in
Europe and Thailand
The European Pregnancy and Paediatric
HIV Cohort Collaboration (EPPICC) study groupM
Objective: The aim of this study was to describe growth during puberty in young
people with vertically acquired HIV.
Design: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand.
Methods: One thousand and ninety-four children initiating a nonnucleoside reverse
transcriptase inhibitor or boosted protease inhibitor based regimen aged 1–10 years
were included. Super Imposition by Translation And Rotation (SITAR) models described
growth from age 8 years using three parameters (average height, timing and shape of the
growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at
antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics
associated with these three parameters.
Results: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8,
9.0] years and1.2 (IQR:2.3 to0.2), respectively. Median follow-up was 9.1 (IQR:
6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently
associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20–
0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years
and 1.50 (1.21–1.78) years later in those starting with HAZ less than3 compared with
HAZ at least 1. Later growth spurts in girls resulted in continued height growth into
later adolescence. In boys starting ART with HAZ less than1, growth spurts were later
in children starting ART in the oldest age group, but for HAZ at least 1, there was no
association with age. Girls and boys who initiated ART with HAZ at least1 maintained
a similar height to the WHO reference mean.
Conclusion: Stunting at ART initiation was associated with later growth spurts in girls.
Children with HAZ at least 1 at ART initiation grew in height at the level expected in
HIV negative children of a comparable age.
Copyright  2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
Although young people living with HIVare at risk for poor
height growth [1], treatment with antiretroviral therapy
(ART) improves growth, with strongest gains in those
treated at a young age [2]. Although initial catch-up growth
on ART has been well described [2], there are less data on
long term growth, particularly during adolescence.
Delays in pubertal development have been reported in
young people with HIV [3–7], with the onset of puberty
[5] and sexual maturation [6] occurring 6 months later
compared with HIV-exposed uninfected young people
(HEU). Earlier puberty in the general population is
associated with being taller and having higher BMI
throughout childhood [8], and poor growth in children
with HIV has been shown to account for much of the
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delay in reaching sexual maturity [6]. There is also
evidence that children starting ARTwith low height-for-
age z-scores experience delays in the onset of puberty
independently of age at ART initiation [3].
Poor growth during childhood can have implications for
future health. Height velocity is associated with increased
HIV replication [9] and progression to AIDS and death
[10] with the association with death being independent of
age, viral load and CD4þ cell count [11]. The timing of
puberty is also inversely associated with bone mass and
density among HIV-negative adolescents [12] and delayed
puberty may increase future risk of osteoporosis among
young people with HIV, who themselves are at risk of
poor bone health, either caused by HIV infection itself or
prolonged exposure to ART [13]. Early growth failure has
also been linked to poorer social and economic outcomes
in later life in the general population [14].
In this study, statistical models that describe an individual’s
growth in terms of mean height throughout adolescence,
and timing and shape of the adolescent growth spurt
were applied to longitudinal height measurements. The
overall aim of this study was to explore the association
between characteristics at ART initiation, in particular
age and height-for-age z-score, and growth during
adolescence.
Materials and methods
Seventeen paediatric HIV cohorts from 15 countries
contributed individual level data to the European
Pregnancy and Paediatric HIV Cohort Collaboration
(EPPICC) between September 2016 and March 2017
using a modified HICDEP protocol (www.hicdep.org).
Pseudo-anonymized data on all children at participating
clinics were included. All cohorts received approval from
local and/or national ethical committees. Five cohorts
from three countries (Italy, Ukraine and three from
Russia) where height data were not routinely collected
(each with <20% of children having a height measure-
ment at ART initiation) were excluded. Children from
the remaining 12 cohorts were eligible provided they
initiated ART with at least two nucleoside reverse
transcriptase inhibitors (NRTIs) along with a nonnucleo-
side reverse transcriptase inhibitor (NNRTI) or boosted
protease inhibitor (bPI); were 1–10 years old at ART
initiation; not known to have horizontally acquired HIV;
and aged at least 8 years at the end of follow-up. We
excluded children initiating ART after age 11 years. For
those initiating ART at an older age, it would be difficult
to distinguish between changes in growth occurring as
a result of a pubertal growth spurt and as a result of
initiating ART. Children with no height recorded at ART
initiation and/or after 8 years of age were excluded.
Height measurements were censored at the earliest of
19th birthday, transfer to adult care, death or loss to
follow-up. Height and BMI were converted to height-
for-age z-scores (HAZ) and BMI-for-age z-scores
(zBMI), using the WHO Growth Standard for measure-
ments when children were aged under 5 years [15] and the
WHO 2007 growth reference when aged 5–18 years
[15,16]. Data checks were carried out to detect
implausible changes in height and/or HAZ. HAZ was
categorized according to WHO definitions as less than
3 SD (severe stunting); 3 to less than 2 SD
(stunting); 2 to less than 1 SD; and at least 1 SD.
zBMI was categorized as less than 2 SD (underweight);
2 to 1 SD (normal); more than 1 to 2 SD (overweight);
and more than 2 SD (obese). HAZ and zBMI nearest
to ART initiation (closest within 6 months before to
1 month after) were considered baseline measurements.
Other variables included were sex, country (Thailand,
UK/Ireland, Rest of Europe), age at ART initiation (1–
2, 3–5 or 6–10 years), initial ART regimen (protease
inhibitor, NNRTI), being born outside the country of
the cohort (’born abroad’) and immunodeficiency at
ART initiation classified using the WHO immunological
classification: none (CD4% >35%, >30%, >25% or
CD4þ cell count>500 cells/ml in children<1, 1–2, 3–4
and 5 years, respectively), mild (CD4% 30–35%, 25–
30%, 20–25% or CD4þ cell count 350–499 cells/ml),
advanced (CD4% 25–29%, 20–24%, 15–19% or CD4þ
cell count 200–349 cells/ml) or severe (CD4% <25%,
<20%, 15–19% or in children >5 CD4þ cell count
<200 cells/ml or CD4% <15%) [17].
Statistical analysis
Characteristics at ART initiation were summarized by
HAZ category. Mean height at age 16 years was
summarized by age and HAZ at ART initiation and
compared with the WHO reference height to quantify
differences in height following the growth spurt. It was
not possible to assess differences in final height, as many
adolescents transfer to adult care from age 16 years,
ending follow-up in EPPICC.
Height was modelled using Super Imposition by
Translation And Rotation (SITAR) models [18]. SITAR
was developed to model growth during childhood and
adolescence and quantifies differences in growth via three
parameters representing the timing and shape of the
adolescent growth spurt, as well as average height. The
models can explain up to 99% of the variation between
individuals’ growth [18] and can be summarized as:
yit ¼ ai þ h
t  bi
expci
 
where the outcome yit is the height of individual i at age
t and h( ) is a natural cubic spline of height over age. The
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parameters ai, bi and ci are participant specific random
effects. ai represents average height throughout adoles-
cence; negative values indicate shorter height overall. bi
represents timing of the pubertal growth spurt; negative
values indicate earlier puberty. ci represents growth
velocity, or the shape of the growth spurt; positive values
indicate shorter growth spurts and a steeper growth
velocity curve, while negative values indicate the growth
spurt occurs over a longer duration. Corresponding
growth velocity curves can also be estimated as the first
derivative of the modelled growth (height) curve.
Age at peak height velocity (APHV) is correlated with
timing of puberty and often used as a proxy for timing of
maturation. It commonly occurs in girls in Tanner stage 2
or 3 and in Tanner stage 3 or 4 for boys [19,20], though
there is variation in timing across Tanner stages [19].
Differences in the timing of the growth spurt estimated
using SITAR models have been shown to be highly
correlated with APHV [18].
All height measurements (in cm) from age 8 (or start of
ART if after 8th birthday) to 18 years were included. Age
and HAZ at ART initiation were added to the SITAR
model as fixed effects that could influence the mean of a, b
and c. Thus, the estimated random effects ai, bi and ci
represent the individual differences in average height,
timing and shape of the growth spurt not associated with
differences in age or height at ART initiation. Models
were fitted separately to boys and girls using a spline with
6 degrees of freedom. Log transformations of both age
and height [18] were considered, but the untransformed
data provided the best fit. Interactions between baseline
height and age were added where appropriate [model
comparison carried out using Bayes Information Criteria
(BIC)].
To explore other factors (sex, country, initial ART
regimen, WHO immunological classification, zBMI at
ART initiation) associated with growth after allowing for
differences in baseline age and height, the estimated ai, bi
and ci random effects from theSITAR modelwere analysed
using multivariable linear regression. Interactions between
each of the factors and sex and between immunological
classification and HAZ and age at ART initiation were
considered. A second model was fitted including zBMI at
age 8 years instead of at ART initiation.
Modelling was repeated in countries where more than 5%
of children were born abroad and more than 5% born in
the country (UK and Ireland, Spain and Netherlands) to
explore differences between those born abroad and those
born in the cohort country. Three sensitivity analyses
were carried out: in the first separate models were fitted
for children from Thailand and elsewhere; in the second
Thai-specific growth reference data were used for Thai
children [21]; and in the third children starting ARTafter
their eighth birthday were excluded.
Analyses were carried out using Stata statistical software
release 15 (StataCorp LP, College Station, Texas, USA)
and the SITAR package [22] in R v3.3.3 (R Core Team,
R Foundation for Statistical Computing, Vienna,
Austria).
Results
Patient characteristics
In total, 1943 young people with HIV initiated ART on
an eligible regimen age 1–10 years and were at least 8
years old at the end of follow-up (Fig. 1). After excluding
those with missing baseline height (n¼ 721) and/or
height after age 8 years (n¼ 202), we included 1094
children in the analysis. Children excluded due to missing
height data were more likely to be from countries other
than Thailand or UK/Ireland, be born abroad and be
younger at ART initiation than those who were included
(Supplementary Table 1, http://links.lww.com/QAD/
B501). The 1094 included children were followed-up for
a median of 9.1 (6.9, 11.4) years after ART initiation.
During this time, 37 325 height measurements were
recorded with a median of 32 (19, 46) per child, of which
25 458 [median 21 (11, 32)] were from age 8 years
onwards. The median time between height measure-
ments was 2.8 (1.4, 3.9) months, with some variation by
cohort ranging from every 1.8 (1.0, 2.8) months in
Thailand to 8.3 (4.7, 11.3) months in Greece.
At ART initiation, median HAZ was 1.2 (2.3, 0.2)
and age was 6.4 (2.8, 9.0) years. Characteristics of children
at ART initiation, stratified by baseline HAZ, are
described in Table 1. More severe stunting was associated
with residence in Thailand, not being born abroad,
initiating on an NNRTI based regimen, earlier calendar
year of ART initiation, higher viral load, more severe
immunodeficiency and lower zBMI at ART initiation.
At the end of the study, 493 (45%) children had reached
their 16th birthday while still in paediatric care (Fig. 1), of
whom 463 (94%) had their height recorded within
6 months of their birthday. Children who survived to age
16 years but were no longer in follow-up in paediatric
care were more likely to reside in Thailand and start ART
at a younger age. At age 16 years, the mean (standard
deviation) heights of boys and girls were 166 (8.7)cm and
158 (6.9)cm, respectively, significantly shorter than the
WHO reference mean height of 173 (7.8)cm for boys and
163 (6.8)cm for girls (both P< 0.001) (Supplementary
Table 2, http://links.lww.com/QAD/B501).
Associations between age and height-for-age
z-score at antiretroviral therapy initiation and
growth from age 8 years
Results from the SITAR models are available in
Supplementary Table 3, http://links.lww.com/QAD/
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B501. Estimated mean height and corresponding growth
velocity curves stratified by HAZ and by age are
summarized in Fig. 2a and b, respectively, for girls and
Fig. 3a and b for boys.
In girls, across each of the baseline HAZ groups (Fig. 2ai–
iv), children starting ART in the oldest age group had
growth spurts on average 0.41 [95% confidence interval
(95% CI) 0.20–0.62] years later than those starting ART
in the youngest age group. Across the baseline age groups
(Fig. 2bi–iii), girls starting ARTwith low HAZ had later
growth spurts; there was a 1.50 (1.21–1.78) year delay in
those with baseline HAZ less than 3 compared with
baseline HAZ at least 1. The effect of this delay on
overall height can be seen in Fig. 2b iv-vi; the differences
in height are smaller from age 16 onwards (after the
growth spurt) than at age 8 years.
In boys, the association between baseline age and the
timing of the growth spurt differed by baseline HAZ
(Fig. 3ai–iv); there was no significant difference by age in
boys who started ARTwith HAZ at least1 (Fig. 3ai). In
boys with baseline HAZ of 2 to less than 1 (Fig. 3aii),
the growth spurt was 0.96 (0.19–1.72) years later in those
starting ART in the oldest compared with the youngest
age group. Similarly, for a baseline HAZ of3 to less than
2 (Fig. 3aiii), the corresponding delay in those starting
ART in the oldest age group was 0.92 (0.17–1.66) years,
and for baseline HAZ less than 3, it was 0.42 (0.32 to
1.16) years (Fig. 3aiv). The timing of the growth spurt
in boys did not differ significantly by baseline HAZ
(Fig. 3bi–iii).
Girls (Fig. 2bv) and boys (Fig. 3bv), who started treatment
with a baseline HAZ at least 1, maintained a similar
mean height to the WHO reference, regardless of baseline
age.
Other factors associated with growth from
age 8 years
Characteristics associated with variations in growth that
remained after adjusting for differences in baseline HAZ
and age are summarized in Table 2. Young people from
Thailand were smaller throughout adolescence than those
from other countries, but did not differ in the timing of the
growth spurt. The shape of the growth spurt differed by
country and was shorter in children from the UK and
Ireland than elsewhere. Lower zBMI at ART initiation was
1900 AIDS 2019, Vol 33 No 12
Fig. 1. Flow chart of participants included in the study.
significantly associated with a later growth spurt [a one SD
decrease was associated with a 0.07 (0.02–0.11) year delay
in the growth spurt]. In a second model (data not shown), a
one SD decrease in zBMI at age 8 years was associated with
a 0.16 (0.09–0.22) year delay in the timing of the growth
spurt, while other parameters did not change substantially.
There was no evidence of any interactions.
In subgroup analysis (n¼ 545), there was a significant
interaction between sex and being born abroad on timing
of the growth spurt (P¼ 0.038). Girls born abroad
experienced a growth spurt 0.24 (0.02–0.46) years earlier
than those born in the cohort country, although there was
no association in boys. However, after adjusting for zBMI
at age 8, the association was no longer significant [growth
spurt for girls born abroad was 0.18 (0.05 to 0.42) years
earlier].
In the three sensitivity analyses wherein models were
fitted separately to children from Thailand and elsewhere,
Thai-specific reference data were used for Thai children
and children starting ART age at least 8 years were
excluded, overall conclusions were unchanged (data not
shown).
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Table 1. Characteristics of 1094 young people living with HIV at antiretroviral therapy initiation stratified by height-for age z-scores.
Height-for-age z-score at ART initiation
N (%) or median (IQR) All
<3 SD
(Severely stunted)
3 to <2 SD
(Stunted)
2 to
<1 SD 1 SD P
All 1094 157 (14) 187 (17) 272 (25) 478 (44)
Male 526 (48) 83 (53) 90 (48) 117 (43) 236 (49) 0.207
Country
UK and Ireland 517 (47) 17 (11) 56 (30) 137 (50) 307 (64) <0.001
Thailand 352 (32) 121 (77) 103 (55) 84 (31) 44 (9)
Othera 225 (21) 19 (12) 28 (15) 51 (19) 127 (27)
Ethnicity
White 99 (9) 10 (6) 12 (6) 26 (10) 51 (11) <0.001
Black 484 (44) 16 (10) 49 (26) 125 (46) 294 (62)
Asian 365 (33) 121 (77) 106 (57) 89 (33) 49 (10)
Other 63 (6) 6 (4) 5 (3) 19 (7) 33 (7)
Unknown/Prohibited 83 (8) 4 (3) 15 (8) 13 (5) 51 (11)
Born abroad 370 (35) 21 (14) 51 (28) 100 (37) 198 (43) <0.001
Age
Median years 6.4 (2.8–9.0) 6.4 (2.7–9.0) 7.1 (3.8–9.5) 6.4 (3.2–8.7) 6.1 (2.5–8.8) <0.001
1 to 2 years 280 (26) 45 (29) 35 (19) 65 (24) 135 (28)
3 to 5 years 237 (22) 31 (20) 43 (23) 64 (24) 99 (21)
6 to 10 years 577 (53) 81 (52) 109 (58) 143 (53) 244 (51)
Year started ART
Median (IQR) 2004 (2003–2007) 2003 (2003–2008) 2004 (200–2006) 2004 (2003–2006) 2005 (2003–2008) <0.001
<2004 433 (40) 79 (50) 78 (42) 116 (43) 160 (33)
2004–2007 445 (41) 69 (44) 93 (50) 106 (39) 177 (37)
2008 216 (20) 9 (6) 16 (9) 50 (18) 141 (30)
NNRTI-based regimen 880 (80) 141 (90) 167 (89) 222 (82) 350 (73) <0.001
Viral load
Value present 980 (90) 133 (85) 167 (89) 241 (89) 439 (92)
Median log VL 5.0 (4.5–5.5) 5.3 (4.9–5.7) 5.0 (4.7–5.5) 5.0 (4.5–5.4) 5.0 (4.2–5.5) <0.001
400 36 (4) 4 (3) 4 (2) 6 (2) 22 (5)
>400 to 1000 13 (1) 1 (1) 1 (1) 1 (0) 10 (2)
>1000–10 000 91 (9) 7 (5) 11 (7) 21 (9) 52 (12)
>10 000–100 000 435 (35) 39 (29) 60 (36) 89 (27) 157 (36)
>100 000 495 (51) 82 (62) 91 (54) 124 (51) 198 (45)
WHO immunological classification
Value present 1006 (92) 145 (92) 177 (95) 258 (95) 426 (89)
None or not significant 164 (16) 7 (5) 16 (9) 40 (16) 101 (24) <0.001
Mild 110 (11) 5 (3) 12 (7) 27 (10) 66 (15)
Advanced 129 (13) 6 (4) 12 (7) 35 (14) 76 (18)
Severe 603 (60) 127 (88) 137 (77) 156 (60) 183 (43)
zBMI
Value present 1089 (100) 157 (100) 186 (100) 271 (100) 475 (99)
Median zBMI 0.1 (1.1 to 0.8) 1.1 (2.3 to 0.2) 0.7 (1.6 to 0.3) 0.1 (0.9 to 0.7) 0.3 (0.5 to 1.1) <0.001
<2 SD (Thinness) 133 (12) 49 (31) 34 (18) 22 (8) 28 (6)
2 to <1 SD 164 (15) 32 (20) 42 (23) 42 (16) 48 (10)
1 to <1 SD 576 (53) 59 (38) 96 (62) 158 (58) 263 (55)
1 to <2 SD (Overweight) 160 (15) 13 (8) 12 (6) 37 (14) 98 (21)
2 SD (Obese) 56 (5) 4 (3) 2 (1) 12 (4) 38 (8)
IQR, interquartile range; VL, viral load; zBMI, BMI-for-age z-scores.
aOther includes Belgium, Greece, Latvia, Netherlands, Poland, Romania, Spain, Sweden and Switzerland.
Discussion
In this study, we described growth throughout adoles-
cence in a large cohort of young people with vertically
acquired HIV in Europe and Thailand. Although all
adolescents in the study initiated ART before age 11
years, growth deficits remained throughout adolescence.
Only children with HAZ at least 1 when starting ART
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Fig. 2. (a)Mean height and growth velocity of girls stratified byHAZ at ART initiation and (b)mean height and growth velocity of
girls stratified by age at ART initiation.
were able to achieve a similar height to the WHO
reference at age 16 years, suggesting that for others, catch
up growth associated with being on ART long term was
not sufficient to restore height to what would be expected
in an HIV-negative population.
We observed an association between older age at ART
initiation and later growth spurts in boys (with HAZ<1
at ART initiation) and girls, in line with findings from the
Antiretroviral research for Watoto (ARROW) trial
wherein attainment of each tanner stage and onset of
menarche was delayed in those starting ARTat older ages
[3]. We also observed an association between stunting and
later growth spurts, but only in girls. The potential role of
anthropometric parameters in early childhood on growth
during puberty was highlighted in a study of 2539 young
people with vertically acquired HIV and HIV-exposed
uninfected (HEU) young people from the USA [6].
Young people living with HIV reached sexual maturity
on average 6 months later than the HEU group, but
differences in HAZ prior to puberty accounted for up to
98% of the delay in boys and (together with zBMI) 74% in
girls, suggesting much of the delay may be attributable to
earlier poor growth [6]. Low HAZ at ART initiation was
also associated with delayed attainment of all Tanner
stages in boys and girls, and menarche in girls,
independently of age at ART initiation in the ARROW
trial [3]. However, in boys, the delay was reduced in those
who had the greatest initial gains in CD4þ cell count after
starting ART, but there was no similar association in girls.
Undernutrition early in life was also found to have a
stronger association with adult height in women than
Pubertal growth in young people with HIV Crichton et al. 1903
Fig. 2. (Continued).
men in the Netherlands [23]. Although this suggests that
girls may be more sensitive to impairments early in life,
and prior to ART, the mechanism underlying potential
sex differences remain to be explained.
After accounting for HAZ and age at ART initiation, we
found no association between WHO immunological
status or viral load at ART initiation and growth.
Similarly, the ARROW trial found immune suppression
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Fig. 3. (a) Mean height and growth velocity of boys stratified by HAZ at ART initiation and (b) mean height and growth velocity
of boys stratified by age at ART initiation.
prior to ARTwas not associated with delayed puberty or
menarche [3]. Other studies have also reported a lack of
association between clinical status at start of puberty and
age at onset [4,7]. However, in young people in the USA,
low CD4þ cell count and high viral load at first pubertal
assessment were associated with later pubertal onset.
Among boys, prior CDC C, low nadir CD4% or high
peak viral load were also associated with later puberty [5].
However, many of these young people initiated ARTon
mono or dual therapy and are likely to have substantially
different treatment histories compared with our study.
We found zBMI at ART initiation and age 8 to be
associated with the timing of the growth spurt, with no
evidence of a difference between boys and girls. We also
observed that girls born abroad experienced an earlier
pubertal growth spurt than girls born in the cohort
country, but the differences in the timing of the growth
spurt reduced after adjusting for zBMI at age 8. In girls, a
relationship between low BMI and delayed puberty has
been found in multiple studies [8] and rapid weight gain
prior to puberty also linked to early onset [24].
Differences between young people born abroad and
those born in the country may therefore be explained by
periods of more rapid weight gain in children arriving
from abroad, the majority from Africa, compared with
those born in the country.
This study had several limitations; as with all observational
studies, our findings on the association between age and
Pubertal growth in young people with HIV Crichton et al. 1905
Fig. 3. (Continued).
HAZ at ART initiation and growth should not be over
interpreted or assumed to be causative. At ART initiation,
stunting was strongly correlated with immunosuppres-
sion, viral load and zBMI and may be a marker for poor
immunological status and other impairments. Children
starting ART at older ages represent a group who have
survived without treatment and possibly with limited
access to care and so may be subject to a survivor bias. Had
ART initiation been delayed in those who started at a
young age, the observed delay in the growth spurt
associated with starting ART at an older age may have
been less in this group who would also have been more
likely to have access to healthcare and regular monitoring.
Nonetheless, the findings provide insight in to growth
patterns among children presenting to care and starting
ART at different ages.
Inclusion criteria applied also lead to the potential for
selection bias. We excluded children with missing height
data. Multiple imputation was not possible, as other data,
such as immunological and virological status, at ART
initiation, likely to be strong predictors of baseline height
were missing in more than half of the children with
missing heights. We excluded young people from Russia,
Ukraine and Italy where height data were not routinely
recorded. Further, the cohorts included in EPPICC range
from national coverage to city hospitals leading to
potential for bias where children treated in large city
hospitals are not representative of others in the country.
Our analyses were restricted to children aged 1–10 years
at ART initiation. The number of infants initiating ART
under age 1 year was small, with high rates of missing
baseline data. A further limitation is the lack of
quantitative measures of pubertal status such as Tanner
stage and date of onset of menarche, which is not
routinely collected by the majority of participating
cohorts. However, differences in timing of the growth
spurt are likely to be indicative of differences in the timing
of onset of puberty.
Finally, we used the WHO growth standard [15] and
growth reference [16] to derive z-scores at ART
initiation. Although the WHO growth standards were
developed to assess growth globally, children from
Thailand were significantly shorter than those residing
in Europe and the WHO reference may overestimate
stunting as compared to Thailand’s own national growth
reference [25]. However, in sensitivity analyses, using
Thai reference data, we did not find any difference in the
associations between baseline HAZ and growth
during adolescence.
Despite these limitations, the study has several strengths.
The collaborative nature of the study provides a rich
source of longitudinal height measurements from a large
sample of young people living with HIV followed during
childhood and adolescence and the use of SITAR models
provides insight into growth during puberty in the
absence of quantitative measures of pubertal status.
In summary, we have shown that children who initiate
ART at younger ages are taller. Children who initiate
ARTwith a ‘normal’ height for age z-score (HAZ 1)
remained with a ‘normal’ height throughout adolescence.
Those who initiated ART stunted or severely stunted
were less likely to achieve ‘normal’ height. We also
demonstrated that in girls, regardless of age at ART
initiation, stunting at time of initiation was associated
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Table 2. Association between characteristics at antiretroviral therapy initiation and average height, timing and shape of growth spurt after
adjustment for baseline age and height-for-age z-score in 918 young people living with HIV.
Average height Timing of growth spurt Shape of growth spurt
coef 95% CI P coef 95% CI P coef 95% CI P
Girls 0.58 0.18 to 1.34 0.132 0.04 0.08 to 0.16 0.485 0.007 0.015 to 0.029 0.555
Country (ref: Other Europe)
Thailand 3.06 4.34 to 1.78 <0.001 0.04 0.16 to 0.24 0.701 0.030 0.067 to 0.007 0.116
UK & Ireland 0.55 1.65 to 0.55 0.325 0.10 0.07 to 0.29 0.241 0.033 0.065 to 0.001 0.044
Year (ref: <2004)
2004 to <2007 0.31 1.17 to 0.55 0.476 0.00 0.14 to 0.14 0.991 0.010 0.015 to 0.035 0.426
2008 0.22 1.33 to 0.90 0.704 0.08 0.26 to 0.10 0.369 0.011 0.022 to 0.043 0.512
NNRTI based regimen
(ref: PI-based regimen)
0.27 0.78 to 1.31 0.616 0.04 0.20 to 0.13 0.673 0.018 0.048 to 0.012 0.240
Viral load (per log increase) 0.10 0.51 to 0.30 0.615 0.03 0.03 to 0.10 0.292 0.002 0.013 to 0.010 0.787
WHO immunological
classification (ref: None)
Mild 0.10 1.56 to 1.35 0.891 0.06 0.17 to 0.29 0.608 0.003 0.045 to 0.039 0.900
Advanced 0.56 1.96 to 0.84 0.433 0.06 0.29 to 0.16 0.581 0.016 0.057 to 0.024 0.426
Severe 0.28 0.84 to 1.39 0.628 0.01 0.18 to 0.17 0.948 0.002 0.034 to 0.031 0.927
zBMI (per 1SD increase) 0.32 0.60 to 0.05 0.021 0.07 0.11 to 0.02 0.003 0.007 0.015 to 0.001 0.083
Individual size, tempo and velocity parameters were estimated using the SITAR model described in the results and table S1, http://links.lww.com/
QAD/B501 and represent the differences in size, tempo and velocity unexplained by age and HAZ at ART initiation. Model included data from 918
of the 1094 children included in the SITAR model for which data on the explanatory variables were complete. CI, confidence interval; NNRTI,
nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; zBMI, BMI-for-age z-scores.
with a later pubertal growth spurt, and this continued
growth into later adolescents may allow those most
severely stunted to catch-up somewhat. However,
longer-term follow-up is required to understand the
potential implications of delayed pubertal growth on
outcomes in later life.
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